Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ACCPL

Accretion Pharmaceuticals Ltd

HealthcarePharmaceuticals & Biotechnology₹224 cr market cap
₹201.55 ▲ +0.0% today As of 19 Nov 2026

Operates in pharmaceutical manufacturing and marketing. Develops formulations across therapeutic categories. Business model includes contract manufacturing and branded generics. Revenue is earned through product sales to distributors. Focuses on compliance-driven production. Serves domestic healthcare markets.

The short version. Promoter holding was 73.52% in Sep 2026, up 0.02 points over 6 quarters.

1 · The price

How has the stock traded?

Change over period: —

4 · The owners

Who holds it, and are they adding?

Promoter holding73.52%

Up 0.02 pts over 6 quarters.

Foreign institutions0.17%

Down 2.05 pts over 6 quarters.

Domestic institutions3.65%

Up 3.56 pts over 6 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter73.573.5273.5273.5273.5273.52+0.02
FII2.221.160000.17-2.05
DII0.090002.763.65+3.56
Public24.1925.3326.4826.4823.7222.66-1.53

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for Accretion Pharmaceuticals Ltd are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about Accretion Pharmaceuticals Ltd

What is the Accretion Pharmaceuticals Ltd share price?

Accretion Pharmaceuticals Ltd (ACCPL) last closed at ₹201.55, up 0.0% on the day.

What is the market cap of Accretion Pharmaceuticals Ltd?

Accretion Pharmaceuticals Ltd has a market capitalisation of about ₹224 crore. Its price-to-earnings ratio is 17.1.

How are Accretion Pharmaceuticals Ltd's latest results?

Promoter holding was 73.52% in Sep 2026, up 0.02 points over 6 quarters.

Who owns Accretion Pharmaceuticals Ltd?

As of Sep 2026, shareholding was: Promoter 73.52%, FII 0.17%, DII 3.65%, Public 22.66%.

How many mutual funds hold Accretion Pharmaceuticals Ltd?

0 mutual fund schemes held Accretion Pharmaceuticals Ltd in October 2026. That compares with 0 the month before.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.